Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 18,635 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503
View directory record Official record
Conditions
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Interventions
LP-284
Drug
Lead sponsor
Lantern Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

NCT02082808
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, DCV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 23, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Macupatide, Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

NCT00357708
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
decitabine, vorinostat, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 23, 2026, 9:08 AM EDT
Recruiting Phase 1 Interventional

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140
View directory record Official record
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813
View directory record Official record
Conditions
Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
Interventions
CX-2029
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 23, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome

NCT06821568
View directory record Official record
Conditions
Alzheimer Disease and Related Dementias, Cognition, Mobility Disability
Interventions
Personalized Transcranial Direct Current Stimulation (tDCS), Active-Sham
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years to 90 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

NCT00003410
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, magnetic resonance imaging, surgical procedure
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Study on Body Composition, Training, Performance, and Recovery

NCT04230824
View directory record Official record
Conditions
Damage Muscle, Body Weight Changes, Performance Enhancing Product Use
Interventions
Pre-workout plus and Protein recovery plus, Placebo, 6-week resistance training program
Dietary Supplement · Other
Lead sponsor
Pharmanex
Industry
Eligibility
25 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 23, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

High Resolution Pharyngeal Manometry (HRPM) Biofeedback

NCT07508059
View directory record Official record
Conditions
Healthy
Interventions
Swallowing Maneuvers, High Resolution Pharyngeal Manometry (HRPM)
Other · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01780662
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
109
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

NCT01791088
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
sirolimus, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

NCT02371603
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
View directory record Official record
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

NCT02194491
View directory record Official record
Conditions
Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers
Interventions
[11C]AS2471907, Positron Emission Tomography (PET), ASP3662
Other · Radiation · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cell Mediated Immunity in Older Adults

NCT01189123
View directory record Official record
Conditions
Immunity to Influenza Vaccine
Interventions
High dose influenza vaccine Sanofi-Pasteur, fluzone by sanofi pasteur
Biological
Lead sponsor
Vanderbilt University
Other
Eligibility
65 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 23, 2026, 9:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Effects of Tai Chi on Frailty in Elderly Adults

NCT01126723
View directory record Official record
Conditions
Frailty
Interventions
Tai Chi, Education-Control
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
70 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes in Emerging Adulthood

NCT04066959
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Motivational Enhancement System (MES), Question Prompt List (QPL), Text Message Reminders (TXT)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 25 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

NCT07851246
View directory record Official record
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
12
States / cities
Glendale, Arizona • Tucson, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STEP Together: An Effectiveness-Implementation Study of Social Incentives and Physical Activity

NCT04942535
View directory record Official record
Conditions
Physical Activity
Interventions
Social Incentive Gamification, Social Goals through Incentives to Charity, Daily Performance Feedback
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
14 Years and older
Enrollment
779 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 23, 2026, 9:08 AM EDT